# SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

# **SCHEDULE 13G**

Under the Securities Exchange Act of 1934 (Amendment No. )\*

# **<u>Quince Therapeutics, Inc.</u>**

(Name of Issuer)

<u>Common Stock, par value \$0.001 per share</u> (Title of Class of Securities)

22053A107

(CUSIP Number)

March 21, 2023 (Date of Event Which Requires Filing of This Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- □ Rule 13d-1(b)
- ý Rule 13d-1(c)
- □ Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1 of 8 Pages

IP No. 22053	A107	13G	Page 2 of 8 Pages			
	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)					
TANG	TANG CAPITAL PARTNERS, LP					
CHECH	K THE APPROPRIATE BC	X IF A MEMBER OF A GROUP*	(a) □ (b) ý			
SEC US	SEC USE ONLY					
CITIZE	CITIZENSHIP OR PLACE OF ORGANIZATION					
DELAV	DELAWARE					
I	5	SOLE VOTING POWER				
SHARES		SHARED VOTING POWER				
OWNI EACH RE	ED BY <b>7</b>	SOLE DISPOSITIVE POWER				
I LKSOI	8	SHARED DISPOSITIVE POWER				
		3,620,000				
,		ICIALLY OWNED BY EACH REPORTING PERSO	Ν			
	3,620,000 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES					
$1 \stackrel{-}{PERCE}$	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9					
9.98%	9.98% TYPE OF REPORTING PERSON					
2	JF KEPURTING PERSON					
PN						

Page 2 of 8 Pages

CUSIP No. 22053A107			13G	Page 3 of 8 Pages		
1	NAMES OF REPORTIN I.R.S. IDENTIFICATIO		NS 7 ABOVE PERSONS (ENTITIES ONLY)	I		
	TANG CAPITAL MAN	AGEMEN	C, LLC			
2	CHECK THE APPROP	RIATE BO	X IF A MEMBER OF A GROUP*	(a) □ (b) ý		
3	SEC USE ONLY					
4	CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE					
E	NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5 6 7 8	SOLE VOTING POWER 0 SHARED VOTING POWER 3,620,000 SOLE DISPOSITIVE POWER 0 SHARED DISPOSITIVE POWER			
9 10 11	3,620,000         AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON         3,620,000         CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES         □         PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9					
12	9.98% Type of reporting OO	FPERSON				

Page 3 of 8 Pages

CUSIP No. 22053A107			13G	Page 4 of 8 Pages		
1	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)					
	KEVIN TANG					
2	CHECK THE APPROP	RIATE BOX	X IF A MEMBER OF A GROUP*	(a) □ (b) ý		
3	SEC USE ONLY					
4	CITIZENSHIP OR PLACE OF ORGANIZATION					
	UNITED STATES					
		5	SOLE VOTING POWER			
SHARES U BENEFICIALLY 3		6	SHARED VOTING POWER 3,620,000			
		7	SOLE DISPOSITIVE POWER			
		8	SHARED DISPOSITIVE POWER			
	ACCRECATE AMOUN		3,620,000			
9		NI BENEFI	CIALLY OWNED BY EACH REPORTING PERSON			
10	3,620,000 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES					
11	⊔ PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9					
12	9.98% TYPE OF REPORTING PERSON					
12	IN					
	μ± <b>1</b>					

Page 4 of 8 Pages

Item 1(a).	Name of Issuer:				
		Quince Therapeutics, Inc., a Delaware corporation (the "Issuer")			
Item 1(b).		Address of Issuer's Principal Executive Offices:			
		601 Gateway Boulevard, Suite 1250, South San Francisco, CA 94080			
Item 2(a).		Name of Person Filing:			
		This Statement on Schedule 13G (this "Statement") is filed by Tang Capital Partners, LP ("Tang Capital Partners"); Tang Capital Management, LLC, the general partner of Tang Capital Partners ("Tang Capital Management"); and Kevin Tang, the manager of Tang Capital Management.			
Item 2(b).		Address of Principal Business Office or, if none, Residence:			
		4747 Executive Drive, Suite 210, San Diego, CA 92121			
Item 2(c).		Citizenship:			
		Tang Capital Partners is a Delaware limited partnership. Tang Capital Management is a Delaware limited liability company. Mr. Tang is a United States citizen.			
Item 2(d).		Title of Class of Securities:			
		Common Stock, par value \$0.001 per share (the "Common Stock")			
Item 2(e).		CUSIP Number: 22053A107			
Item 3. Not applicable.		pplicable.			
Item 4.	Owne	ership.			
	(a)	Amount Beneficially Owned:			
		Tang Capital Partners. Tang Capital Partners beneficially owns 3,620,000 shares of the Issuer's Common Stock.			
		Tang Capital Partners shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang.			
		Tang Capital Management. Tang Capital Management beneficially owns 3,620,000 shares of the Issuer's Common Stock.			
		Tang Capital Management shares voting and dispositive power over such shares with Tang Capital Partners and Kevin Tang.			
		Kevin Tang. Kevin Tang beneficially owns 3,620,000 shares of the Issuer's Common Stock.			
		Kevin Tang shares voting and dispositive power over such shares with Tang Capital Partners and Tang Capital Management.			

Page 5 of 8 Pages

The percentages used herein are based on 36,276,945 shares of Common Stock outstanding as of March 10, 2023, as set forth in the Issuer's Annual Report filed on Form 10-K that was filed with the Securities and Exchange Commission on March 15, 2023.

(b) Percent of Class:

	Tang	g Capital Partners g Capital Management in Tang	9.98% 9.98% 9.98%	
(c)	Nun	aber of shares as to which such person has:		
	(i)	sole power to vote or to direct the vote:		
		Tang Capital Partners Tang Capital Management Kevin Tang	0 shares 0 shares 0 shares	
	(ii)	shared power to vote or to direct the vote:		
		Tang Capital Partners Tang Capital Management Kevin Tang	3,620,000 shares 3,620,000 shares 3,620,000 shares	
	(iii)	sole power to dispose or to direct the disposition of:		
		Tang Capital Partners Tang Capital Management Kevin Tang	0 shares 0 shares 0 shares	
	(iv)			
		Tang Capital Partners Tang Capital Management	3,620,000 shares 3,620,000 shares	

#### Item 5. Ownership of Five Percent or Less of a Class.

Kevin Tang

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: o

3,620,000 shares

## Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable

#### Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

Not applicable.

### Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Page 6 of 8 Pages

# Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

# SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: March 31, 2023

TANG CAPITAL PARTNERS, LP

By: Tang Capital Management, LLC, its General Partner

By: /s/ Kevin Tang Kevin Tang, Manager

#### TANG CAPITAL MANAGEMENT, LLC

By: /s/ Kevin Tang Kevin Tang, Manager

/s/ Kevin Tang Kevin Tang

Page 8 of 8 Pages

#### JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, \$0.001 par value per share, of Quince Therapeutics, Inc. and further agree to the filing of this agreement as an exhibit thereto. In addition, each party to this Agreement expressly authorizes each other party to this Agreement to file on its behalf any and all amendments to such Statement on Schedule 13G.

Date: March 31, 2023

#### TANG CAPITAL PARTNERS, LP

- By: Tang Capital Management, LLC
- Its: General Partner
- By: /s/ Kevin Tang Name: Kevin Tang Title: Manager

#### TANG CAPITAL MANAGEMENT, LLC

By: /s/ Kevin Tang Name: Kevin Tang Title: Manager

/s/ Kevin Tang

Name: Kevin Tang